Abstract Number: 1622 • 2013 ACR/ARHP Annual Meeting
Deep-Sequencing Reveals Class-Specific Urinary Micrornas In Human Lupus Nephritis
Background/Purpose: Lupus nephritis (LN), particularly, ISN/RPS class IV LN, is associated with significant morbidity and mortality. microRNAs (miRs) are small, non-coding RNAs that regulate translation.…Abstract Number: 1582 • 2013 ACR/ARHP Annual Meeting
The Accrual Of Damage In Corticosteroid-Naïve Patients With Systemic Lupus Erythematosus
Background/Purpose: Despite improved survival rates in systemic lupus erythematosus (SLE) over the last 4 decades, organ damage and associated morbidity continues over time. Corticosteroids (CS)…Abstract Number: 1597 • 2013 ACR/ARHP Annual Meeting
Autonomic Dysfunction In Systemic Lupus Erythematosus Patients With Previous Neuropsychiatric Involvement
Background/Purpose: Autonomic dysfunction has increasingly been described to be associated with central nervous system (CNS) disorders and has been attributed to damage of the central…Abstract Number: 1583 • 2013 ACR/ARHP Annual Meeting
Serositis In Systemic Lupus Erythematosus: Prevalence, Recurrence, Treatment and Outcome
Background/Purpose: Serositis is one of the ACR classification criteria for SLE. Its incidence is variable in studies varying from 12 to 60%. The aim of…Abstract Number: 1584 • 2013 ACR/ARHP Annual Meeting
Clinical Correlates Of Chronic Isolated Thrombocytopenia In Patients With Systemic Lupus Erythematosus
Background/Purpose: Past studies have revealed disparity in the clinical significance of thrombocytopenia in systemic lupus erythematosus (SLE), ranging from a benign and incidental finding in…Abstract Number: 1585 • 2013 ACR/ARHP Annual Meeting
Corticosteroid Use Across 52 Weeks Of Belimumab Therapy In Patients With Systemic Lupus Erythematosus: Combined Analyses From The BLISS Trials
Background/Purpose: Patients with systemic lupus erythematosus (SLE) frequently receive corticosteroids (CS) as standard therapy. We examined the effects of belimumab on CS dose across 52…Abstract Number: 1586 • 2013 ACR/ARHP Annual Meeting
Defining Hand Arthritis In Systemic Lupus Erythematosus, From An Ultrasound, Magnetic Resonance Imaging and Antibody Status Perspective
Background/Purpose: Musculoskeletal involvement in systemic lupus erythematosus (SLE) is common but poorly characterised with only a few Magnetic Resonance Imaging (MRI) or ultrasound (US) studies…Abstract Number: 1587 • 2013 ACR/ARHP Annual Meeting
Continuous Variables Of Treatment Interventions In Patients Diagnosed With Systemic Lupus Erythematosus Among Commercially and Medicaid Insured Populations In The U.S
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs including the heart, lungs, kidneys, joints, and the nervous system. Standard…Abstract Number: 1588 • 2013 ACR/ARHP Annual Meeting
Poor Adherence To Medications For Systemic Lupus Erythematosus Among U.S. Medicaid Beneficiaries
Background/Purpose: Immunosuppressive and anti-malarial drugs are the cornerstones of treatment for patients with systemic lupus erythematosus (SLE) and have been shown to improve outcomes,…Abstract Number: 1589 • 2013 ACR/ARHP Annual Meeting
Obesity and Vascular Factors May Play a Role In Persistent Depression Among Individuals With Systemic Lupus Erythematosus
Background/Purpose: Depression is commonly reported in systemic lupus erythematosus (SLE), yet information is lacking about long-term patterns of depression. In particular, because depression is thought…Abstract Number: 1590 • 2013 ACR/ARHP Annual Meeting
A CD8 T Cell-IFN-γ-IDO Axis Is Required For Mesenchymal Stem Cell Suppression Of Human SLE
Background/Purpose: Stem cell-based regenerative medicine is a promising approach in tissue reconstruction. Mesenchymal stem cells (MSC) show therapeutic effects on human autoimmune diseases including systemic…Abstract Number: 1591 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Atacicept For Prevention Of Flares In Subjects With Moderate To Severe Systemic Lupus Erythematosus (SLE)
Background/Purpose: Atacicept is a fusion protein that inhibits B-cell stimulation factors BLyS and APRIL. Levels of BLyS and APRIL are elevated in patients with SLE.…Abstract Number: 1592 • 2013 ACR/ARHP Annual Meeting
“Lupus Headache”: Results From a Prospective, International, Inception Cohort Study
Background/Purpose: “Lupus headache” is controversial and is included in validated measures of global SLE disease activity. We examined the frequency and characteristics of “lupus headache”…Abstract Number: 1594 • 2013 ACR/ARHP Annual Meeting
Cognitive Dysfunction, Depression and Anti N-Methyl-D-Aspartate Receptor Antibodies and Anti- Ribosomal P In Systemic Lupus Erythematosus Patients In Argentina
Background/Purpose: Cognitive dysfunction (CD) and depression (D) are common manifestations of neuropsychiatric systemic lupus erythematosus (SLE) and they have been linked to antibodies (abs) like…Abstract Number: 1595 • 2013 ACR/ARHP Annual Meeting
Electroclinical Correlates and Outcome Of Status Epilepticus In Systemic Lupus Erythematosus
Background/Purpose: Predictors of seizures and epilepsy in systemic lupus erythematosus (SLE) patients are well described but descriptions of status epilepticus (SE) have thus far been…